nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Scotoma—Docetaxel—skin cancer	0.00448	0.00448	CcSEcCtD
Brimonidine—Abnormal vision—Temozolomide—skin cancer	0.00446	0.00446	CcSEcCtD
Brimonidine—Photophobia—Fluorouracil—skin cancer	0.00443	0.00443	CcSEcCtD
Brimonidine—Erythema—Vemurafenib—skin cancer	0.00438	0.00438	CcSEcCtD
Brimonidine—Coma—Fluorouracil—skin cancer	0.00431	0.00431	CcSEcCtD
Brimonidine—Rhinitis—Imiquimod—skin cancer	0.0043	0.0043	CcSEcCtD
Brimonidine—Dysgeusia—Vemurafenib—skin cancer	0.00429	0.00429	CcSEcCtD
Brimonidine—Pharyngitis—Imiquimod—skin cancer	0.00426	0.00426	CcSEcCtD
Brimonidine—Lethargy—Dactinomycin—skin cancer	0.00419	0.00419	CcSEcCtD
Brimonidine—Asthenia—Vismodegib—skin cancer	0.00415	0.00415	CcSEcCtD
Brimonidine—Visual impairment—Imiquimod—skin cancer	0.00413	0.00413	CcSEcCtD
Brimonidine—Eye pain—Temozolomide—skin cancer	0.00411	0.00411	CcSEcCtD
Brimonidine—Pruritus—Vismodegib—skin cancer	0.00409	0.00409	CcSEcCtD
Brimonidine—Nasal congestion—Temozolomide—skin cancer	0.00408	0.00408	CcSEcCtD
Brimonidine—Eye disorder—Imiquimod—skin cancer	0.00401	0.00401	CcSEcCtD
Brimonidine—Eye irritation—Docetaxel—skin cancer	0.00398	0.00398	CcSEcCtD
Brimonidine—Flushing—Imiquimod—skin cancer	0.00398	0.00398	CcSEcCtD
Brimonidine—Angiopathy—Imiquimod—skin cancer	0.00389	0.00389	CcSEcCtD
Brimonidine—Swelling—Fluorouracil—skin cancer	0.00388	0.00388	CcSEcCtD
Brimonidine—Immune system disorder—Imiquimod—skin cancer	0.00387	0.00387	CcSEcCtD
Brimonidine—Mediastinal disorder—Imiquimod—skin cancer	0.00386	0.00386	CcSEcCtD
Brimonidine—Arrhythmia—Imiquimod—skin cancer	0.00383	0.00383	CcSEcCtD
Brimonidine—Cough—Vemurafenib—skin cancer	0.00382	0.00382	CcSEcCtD
Brimonidine—Mental disorder—Imiquimod—skin cancer	0.00376	0.00376	CcSEcCtD
Brimonidine—Erythema—Imiquimod—skin cancer	0.00373	0.00373	CcSEcCtD
Brimonidine—Arthralgia—Vemurafenib—skin cancer	0.00373	0.00373	CcSEcCtD
Brimonidine—Myalgia—Vemurafenib—skin cancer	0.00373	0.00373	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.0037	0.0037	CcSEcCtD
Brimonidine—Lacrimation increased—Docetaxel—skin cancer	0.00369	0.00369	CcSEcCtD
Brimonidine—Rash—Vismodegib—skin cancer	0.00365	0.00365	CcSEcCtD
Brimonidine—Dermatitis—Vismodegib—skin cancer	0.00364	0.00364	CcSEcCtD
Brimonidine—Face oedema—Temozolomide—skin cancer	0.00359	0.00359	CcSEcCtD
Brimonidine—Infection—Vemurafenib—skin cancer	0.00355	0.00355	CcSEcCtD
Brimonidine—Nervous system disorder—Vemurafenib—skin cancer	0.0035	0.0035	CcSEcCtD
Brimonidine—Lethargy—Fluorouracil—skin cancer	0.00349	0.00349	CcSEcCtD
Brimonidine—Skin disorder—Vemurafenib—skin cancer	0.00347	0.00347	CcSEcCtD
Brimonidine—Respiratory failure—Docetaxel—skin cancer	0.00346	0.00346	CcSEcCtD
Brimonidine—Nausea—Vismodegib—skin cancer	0.00343	0.00343	CcSEcCtD
Brimonidine—Osteoarthritis—Fluorouracil—skin cancer	0.00342	0.00342	CcSEcCtD
Brimonidine—Dry skin—Temozolomide—skin cancer	0.0034	0.0034	CcSEcCtD
Brimonidine—Syncope—Imiquimod—skin cancer	0.00335	0.00335	CcSEcCtD
Brimonidine—Hypotension—Vemurafenib—skin cancer	0.00334	0.00334	CcSEcCtD
Brimonidine—Palpitations—Imiquimod—skin cancer	0.0033	0.0033	CcSEcCtD
Brimonidine—Loss of consciousness—Imiquimod—skin cancer	0.00328	0.00328	CcSEcCtD
Brimonidine—Cough—Imiquimod—skin cancer	0.00326	0.00326	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00325	0.00325	CcSEcCtD
Brimonidine—Hypertension—Imiquimod—skin cancer	0.00322	0.00322	CcSEcCtD
Brimonidine—Arthralgia—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Brimonidine—Chest pain—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Brimonidine—Myalgia—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Brimonidine—Anxiety—Imiquimod—skin cancer	0.00317	0.00317	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00316	0.00316	CcSEcCtD
Brimonidine—Discomfort—Imiquimod—skin cancer	0.00314	0.00314	CcSEcCtD
Brimonidine—Dry skin—Fluorouracil—skin cancer	0.00314	0.00314	CcSEcCtD
Brimonidine—Dry mouth—Imiquimod—skin cancer	0.00311	0.00311	CcSEcCtD
Brimonidine—Bronchitis—Temozolomide—skin cancer	0.00309	0.00309	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00308	0.00308	CcSEcCtD
Brimonidine—Fatigue—Vemurafenib—skin cancer	0.00308	0.00308	CcSEcCtD
Brimonidine—Nasopharyngitis—Fluorouracil—skin cancer	0.00306	0.00306	CcSEcCtD
Brimonidine—Oedema—Imiquimod—skin cancer	0.00305	0.00305	CcSEcCtD
Brimonidine—Infection—Imiquimod—skin cancer	0.00303	0.00303	CcSEcCtD
Brimonidine—Shock—Imiquimod—skin cancer	0.003	0.003	CcSEcCtD
Brimonidine—Nervous system disorder—Imiquimod—skin cancer	0.00299	0.00299	CcSEcCtD
Brimonidine—Tachycardia—Imiquimod—skin cancer	0.00297	0.00297	CcSEcCtD
Brimonidine—Skin disorder—Imiquimod—skin cancer	0.00296	0.00296	CcSEcCtD
Brimonidine—Depression—Temozolomide—skin cancer	0.00285	0.00285	CcSEcCtD
Brimonidine—Flushing—Bleomycin—skin cancer	0.00283	0.00283	CcSEcCtD
Brimonidine—Pharyngitis—Dactinomycin—skin cancer	0.00282	0.00282	CcSEcCtD
Brimonidine—Swelling—Docetaxel—skin cancer	0.0028	0.0028	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00278	0.00278	CcSEcCtD
Brimonidine—Insomnia—Imiquimod—skin cancer	0.00275	0.00275	CcSEcCtD
Brimonidine—Paraesthesia—Imiquimod—skin cancer	0.00274	0.00274	CcSEcCtD
Brimonidine—Dyspnoea—Imiquimod—skin cancer	0.00272	0.00272	CcSEcCtD
Brimonidine—Somnolence—Imiquimod—skin cancer	0.00271	0.00271	CcSEcCtD
Brimonidine—Sinusitis—Temozolomide—skin cancer	0.00269	0.00269	CcSEcCtD
Brimonidine—Dyspepsia—Imiquimod—skin cancer	0.00268	0.00268	CcSEcCtD
Brimonidine—Erythema—Bleomycin—skin cancer	0.00265	0.00265	CcSEcCtD
Brimonidine—Flushing—Dactinomycin—skin cancer	0.00264	0.00264	CcSEcCtD
Brimonidine—Hypersensitivity—Vemurafenib—skin cancer	0.00263	0.00263	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00263	0.00263	CcSEcCtD
Brimonidine—Fatigue—Imiquimod—skin cancer	0.00263	0.00263	CcSEcCtD
Brimonidine—Visual disturbance—Docetaxel—skin cancer	0.00261	0.00261	CcSEcCtD
Brimonidine—Pain—Imiquimod—skin cancer	0.0026	0.0026	CcSEcCtD
Brimonidine—Conjunctivitis—Fluorouracil—skin cancer	0.00256	0.00256	CcSEcCtD
Brimonidine—Asthenia—Vemurafenib—skin cancer	0.00256	0.00256	CcSEcCtD
Brimonidine—Pharyngitis—Temozolomide—skin cancer	0.00255	0.00255	CcSEcCtD
Brimonidine—Pruritus—Vemurafenib—skin cancer	0.00253	0.00253	CcSEcCtD
Brimonidine—Lethargy—Docetaxel—skin cancer	0.00252	0.00252	CcSEcCtD
Brimonidine—Visual impairment—Temozolomide—skin cancer	0.00248	0.00248	CcSEcCtD
Brimonidine—Sinusitis—Fluorouracil—skin cancer	0.00247	0.00247	CcSEcCtD
Brimonidine—Erythema—Dactinomycin—skin cancer	0.00247	0.00247	CcSEcCtD
Brimonidine—Eye disorder—Temozolomide—skin cancer	0.0024	0.0024	CcSEcCtD
Brimonidine—Cardiac disorder—Temozolomide—skin cancer	0.00238	0.00238	CcSEcCtD
Brimonidine—Flushing—Temozolomide—skin cancer	0.00238	0.00238	CcSEcCtD
Brimonidine—Rhinitis—Fluorouracil—skin cancer	0.00237	0.00237	CcSEcCtD
Brimonidine—Dizziness—Vemurafenib—skin cancer	0.00236	0.00236	CcSEcCtD
Brimonidine—Pharyngitis—Fluorouracil—skin cancer	0.00235	0.00235	CcSEcCtD
Brimonidine—Angiopathy—Temozolomide—skin cancer	0.00233	0.00233	CcSEcCtD
Brimonidine—Immune system disorder—Temozolomide—skin cancer	0.00232	0.00232	CcSEcCtD
Brimonidine—Mediastinal disorder—Temozolomide—skin cancer	0.00232	0.00232	CcSEcCtD
Brimonidine—Cough—Bleomycin—skin cancer	0.00231	0.00231	CcSEcCtD
Brimonidine—Dry skin—Docetaxel—skin cancer	0.00226	0.00226	CcSEcCtD
Brimonidine—Myalgia—Bleomycin—skin cancer	0.00226	0.00226	CcSEcCtD
Brimonidine—Chest pain—Bleomycin—skin cancer	0.00226	0.00226	CcSEcCtD
Brimonidine—Rash—Vemurafenib—skin cancer	0.00225	0.00225	CcSEcCtD
Brimonidine—Mental disorder—Temozolomide—skin cancer	0.00225	0.00225	CcSEcCtD
Brimonidine—Dermatitis—Vemurafenib—skin cancer	0.00225	0.00225	CcSEcCtD
Brimonidine—Hypersensitivity—Imiquimod—skin cancer	0.00224	0.00224	CcSEcCtD
Brimonidine—Headache—Vemurafenib—skin cancer	0.00224	0.00224	CcSEcCtD
Brimonidine—Erythema—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Brimonidine—Discomfort—Bleomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Brimonidine—Nasopharyngitis—Docetaxel—skin cancer	0.00221	0.00221	CcSEcCtD
Brimonidine—Dysgeusia—Temozolomide—skin cancer	0.00219	0.00219	CcSEcCtD
Brimonidine—Asthenia—Imiquimod—skin cancer	0.00219	0.00219	CcSEcCtD
Brimonidine—Oedema—Bleomycin—skin cancer	0.00216	0.00216	CcSEcCtD
Brimonidine—Pruritus—Imiquimod—skin cancer	0.00216	0.00216	CcSEcCtD
Brimonidine—Infection—Bleomycin—skin cancer	0.00215	0.00215	CcSEcCtD
Brimonidine—Nausea—Vemurafenib—skin cancer	0.00212	0.00212	CcSEcCtD
Brimonidine—Arrhythmia—Fluorouracil—skin cancer	0.00211	0.00211	CcSEcCtD
Brimonidine—Vision blurred—Temozolomide—skin cancer	0.00211	0.00211	CcSEcCtD
Brimonidine—Myalgia—Dactinomycin—skin cancer	0.00211	0.00211	CcSEcCtD
Brimonidine—Discomfort—Dactinomycin—skin cancer	0.00208	0.00208	CcSEcCtD
Brimonidine—Erythema—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Brimonidine—Hypotension—Bleomycin—skin cancer	0.00202	0.00202	CcSEcCtD
Brimonidine—Oedema—Dactinomycin—skin cancer	0.00202	0.00202	CcSEcCtD
Brimonidine—Dizziness—Imiquimod—skin cancer	0.00201	0.00201	CcSEcCtD
Brimonidine—Infection—Dactinomycin—skin cancer	0.002	0.002	CcSEcCtD
Brimonidine—Palpitations—Temozolomide—skin cancer	0.00198	0.00198	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00197	0.00197	CcSEcCtD
Brimonidine—Cough—Temozolomide—skin cancer	0.00195	0.00195	CcSEcCtD
Brimonidine—Paraesthesia—Bleomycin—skin cancer	0.00194	0.00194	CcSEcCtD
Brimonidine—Vision blurred—Fluorouracil—skin cancer	0.00194	0.00194	CcSEcCtD
Brimonidine—Hypertension—Temozolomide—skin cancer	0.00193	0.00193	CcSEcCtD
Brimonidine—Dyspnoea—Bleomycin—skin cancer	0.00193	0.00193	CcSEcCtD
Brimonidine—Rash—Imiquimod—skin cancer	0.00192	0.00192	CcSEcCtD
Brimonidine—Dermatitis—Imiquimod—skin cancer	0.00192	0.00192	CcSEcCtD
Brimonidine—Headache—Imiquimod—skin cancer	0.00191	0.00191	CcSEcCtD
Brimonidine—Myalgia—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Brimonidine—Arthralgia—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Brimonidine—Anxiety—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00189	0.00189	CcSEcCtD
Brimonidine—Discomfort—Temozolomide—skin cancer	0.00188	0.00188	CcSEcCtD
Brimonidine—Dry mouth—Temozolomide—skin cancer	0.00186	0.00186	CcSEcCtD
Brimonidine—Pain—Bleomycin—skin cancer	0.00185	0.00185	CcSEcCtD
Brimonidine—Conjunctivitis—Docetaxel—skin cancer	0.00185	0.00185	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00184	0.00184	CcSEcCtD
Brimonidine—Oedema—Temozolomide—skin cancer	0.00183	0.00183	CcSEcCtD
Brimonidine—Infection—Temozolomide—skin cancer	0.00181	0.00181	CcSEcCtD
Brimonidine—Nausea—Imiquimod—skin cancer	0.00181	0.00181	CcSEcCtD
Brimonidine—Nervous system disorder—Temozolomide—skin cancer	0.00179	0.00179	CcSEcCtD
Brimonidine—Skin disorder—Temozolomide—skin cancer	0.00177	0.00177	CcSEcCtD
Brimonidine—Myalgia—Fluorouracil—skin cancer	0.00175	0.00175	CcSEcCtD
Brimonidine—Chest pain—Fluorouracil—skin cancer	0.00175	0.00175	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—skin cancer	0.00174	0.00174	CcSEcCtD
Brimonidine—Discomfort—Fluorouracil—skin cancer	0.00173	0.00173	CcSEcCtD
Brimonidine—Pain—Dactinomycin—skin cancer	0.00173	0.00173	CcSEcCtD
Brimonidine—Rhinitis—Docetaxel—skin cancer	0.00171	0.00171	CcSEcCtD
Brimonidine—Pharyngitis—Docetaxel—skin cancer	0.0017	0.0017	CcSEcCtD
Brimonidine—Oedema—Fluorouracil—skin cancer	0.00168	0.00168	CcSEcCtD
Brimonidine—Infection—Fluorouracil—skin cancer	0.00167	0.00167	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Brimonidine—Insomnia—Temozolomide—skin cancer	0.00165	0.00165	CcSEcCtD
Brimonidine—Nervous system disorder—Fluorouracil—skin cancer	0.00165	0.00165	CcSEcCtD
Brimonidine—Visual impairment—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
Brimonidine—Tachycardia—Fluorouracil—skin cancer	0.00164	0.00164	CcSEcCtD
Brimonidine—Paraesthesia—Temozolomide—skin cancer	0.00164	0.00164	CcSEcCtD
Brimonidine—Dyspnoea—Temozolomide—skin cancer	0.00163	0.00163	CcSEcCtD
Brimonidine—Somnolence—Temozolomide—skin cancer	0.00162	0.00162	CcSEcCtD
Brimonidine—Dyspepsia—Temozolomide—skin cancer	0.00161	0.00161	CcSEcCtD
Brimonidine—Eye disorder—Docetaxel—skin cancer	0.0016	0.0016	CcSEcCtD
Brimonidine—Hypersensitivity—Bleomycin—skin cancer	0.00159	0.00159	CcSEcCtD
Brimonidine—Cardiac disorder—Docetaxel—skin cancer	0.00159	0.00159	CcSEcCtD
Brimonidine—Flushing—Docetaxel—skin cancer	0.00159	0.00159	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00158	0.00158	CcSEcCtD
Brimonidine—Fatigue—Temozolomide—skin cancer	0.00157	0.00157	CcSEcCtD
Brimonidine—Hypotension—Fluorouracil—skin cancer	0.00157	0.00157	CcSEcCtD
Brimonidine—Pain—Temozolomide—skin cancer	0.00156	0.00156	CcSEcCtD
Brimonidine—Asthenia—Bleomycin—skin cancer	0.00155	0.00155	CcSEcCtD
Brimonidine—Angiopathy—Docetaxel—skin cancer	0.00155	0.00155	CcSEcCtD
Brimonidine—Immune system disorder—Docetaxel—skin cancer	0.00154	0.00154	CcSEcCtD
Brimonidine—Mediastinal disorder—Docetaxel—skin cancer	0.00154	0.00154	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00153	0.00153	CcSEcCtD
Brimonidine—Pruritus—Bleomycin—skin cancer	0.00153	0.00153	CcSEcCtD
Brimonidine—Arrhythmia—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Brimonidine—Insomnia—Fluorouracil—skin cancer	0.00152	0.00152	CcSEcCtD
Brimonidine—Paraesthesia—Fluorouracil—skin cancer	0.00151	0.00151	CcSEcCtD
Brimonidine—Dyspnoea—Fluorouracil—skin cancer	0.0015	0.0015	CcSEcCtD
Brimonidine—Mental disorder—Docetaxel—skin cancer	0.0015	0.0015	CcSEcCtD
Brimonidine—Somnolence—Fluorouracil—skin cancer	0.0015	0.0015	CcSEcCtD
Brimonidine—Erythema—Docetaxel—skin cancer	0.00149	0.00149	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—skin cancer	0.00149	0.00149	CcSEcCtD
Brimonidine—Dyspepsia—Fluorouracil—skin cancer	0.00148	0.00148	CcSEcCtD
Brimonidine—Dysgeusia—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00145	0.00145	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—skin cancer	0.00145	0.00145	CcSEcCtD
Brimonidine—Pain—Fluorouracil—skin cancer	0.00144	0.00144	CcSEcCtD
Brimonidine—Rash—Bleomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Brimonidine—Dermatitis—Bleomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Brimonidine—Hypersensitivity—Temozolomide—skin cancer	0.00134	0.00134	CcSEcCtD
Brimonidine—Syncope—Docetaxel—skin cancer	0.00133	0.00133	CcSEcCtD
Brimonidine—Palpitations—Docetaxel—skin cancer	0.00131	0.00131	CcSEcCtD
Brimonidine—Asthenia—Temozolomide—skin cancer	0.00131	0.00131	CcSEcCtD
Brimonidine—Loss of consciousness—Docetaxel—skin cancer	0.00131	0.00131	CcSEcCtD
Brimonidine—Cough—Docetaxel—skin cancer	0.0013	0.0013	CcSEcCtD
Brimonidine—Pruritus—Temozolomide—skin cancer	0.00129	0.00129	CcSEcCtD
Brimonidine—Nausea—Bleomycin—skin cancer	0.00129	0.00129	CcSEcCtD
Brimonidine—Hypertension—Docetaxel—skin cancer	0.00128	0.00128	CcSEcCtD
Brimonidine—Rash—Dactinomycin—skin cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Brimonidine—Hypersensitivity—Fluorouracil—skin cancer	0.00124	0.00124	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—skin cancer	0.00124	0.00124	CcSEcCtD
Brimonidine—Oedema—Docetaxel—skin cancer	0.00121	0.00121	CcSEcCtD
Brimonidine—Dizziness—Temozolomide—skin cancer	0.00121	0.00121	CcSEcCtD
Brimonidine—Infection—Docetaxel—skin cancer	0.00121	0.00121	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—skin cancer	0.0012	0.0012	CcSEcCtD
Brimonidine—Shock—Docetaxel—skin cancer	0.00119	0.00119	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—skin cancer	0.00119	0.00119	CcSEcCtD
Brimonidine—Pruritus—Fluorouracil—skin cancer	0.00119	0.00119	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—skin cancer	0.00118	0.00118	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—skin cancer	0.00118	0.00118	CcSEcCtD
Brimonidine—Rash—Temozolomide—skin cancer	0.00115	0.00115	CcSEcCtD
Brimonidine—Dermatitis—Temozolomide—skin cancer	0.00115	0.00115	CcSEcCtD
Brimonidine—Headache—Temozolomide—skin cancer	0.00114	0.00114	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—skin cancer	0.00113	0.00113	CcSEcCtD
Brimonidine—Dizziness—Fluorouracil—skin cancer	0.00111	0.00111	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—skin cancer	0.00109	0.00109	CcSEcCtD
Brimonidine—Nausea—Temozolomide—skin cancer	0.00108	0.00108	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—skin cancer	0.00108	0.00108	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—skin cancer	0.00108	0.00108	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—skin cancer	0.00107	0.00107	CcSEcCtD
Brimonidine—Rash—Fluorouracil—skin cancer	0.00106	0.00106	CcSEcCtD
Brimonidine—Dermatitis—Fluorouracil—skin cancer	0.00106	0.00106	CcSEcCtD
Brimonidine—Headache—Fluorouracil—skin cancer	0.00105	0.00105	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
Brimonidine—Pain—Docetaxel—skin cancer	0.00104	0.00104	CcSEcCtD
Brimonidine—Nausea—Fluorouracil—skin cancer	0.000999	0.000999	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—skin cancer	0.000894	0.000894	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—skin cancer	0.000871	0.000871	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—skin cancer	0.000859	0.000859	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—skin cancer	0.000803	0.000803	CcSEcCtD
Brimonidine—Rash—Docetaxel—skin cancer	0.000765	0.000765	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—skin cancer	0.000765	0.000765	CcSEcCtD
Brimonidine—Headache—Docetaxel—skin cancer	0.00076	0.00076	CcSEcCtD
Brimonidine—Nausea—Docetaxel—skin cancer	0.000721	0.000721	CcSEcCtD
